Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages

Urology

Volumn 124, Issue , 2019, Pages 120-126

  Khanna, Abhinav ^a   Yerram, Nitin ^a   Zhu, Hui ^b   Kim, Simon ^c   Abouassaly, Robert ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; CYSTECTOMY; DRUG SHORTAGE; DRUG UTILIZATION; ETHNIC DIFFERENCE; FEMALE; HIGH VOLUME HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; MIDDLE AGED; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; UNIVERSITY HOSPITAL; VERY ELDERLY; BLADDER TUMOR; PATHOLOGY; SUPPLY AND DISTRIBUTION; TUMOR INVASION;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; BCG VACCINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 85058225484     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2018.07.055     Document Type: Article

References (27)

1. Chang, SS, Boorjian, SA, Chou, R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196 (2016), 1021–1029, 10.1016/j.juro.2016.06.049.
2. Spiess, PE, Agarwal, N, Bangs, R, et al. Bladder cancer, Version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15 (2017), 1240–1267, 10.6004/jnccn.2017.0156.
3. Babjuk, M, Böhle, A, Burger, M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71 (2017), 447–461, 10.1016/j.eururo.2016.05.041.
4. Shelley, MD, Wilt, TJ, Court, J, Coles, B, Kynaston, H, Mason, MD, Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004), 485–490 http://www.ncbi.nlm.nih.gov/pubmed/15008714.
5. Shelley, MD, Mason, MD, Kynaston, H, Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 36 (2010), 195–205, 10.1016/j.ctrv.2009.12.005.
6. Malmström, P-U, Sylvester, RJ, Crawford, DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009), 247–256, 10.1016/j.eururo.2009.04.038.
7. Sanofi Pasteur. Sanofi Pasteur Statement on Discontinuation of BCG. http://www.sanofipasteur.ca/node/50701. Accessed January 8, 2017.
8. Meeks, JJ, Lerner, SP, Svatek, RS, Bacillus Calmette-Guérin manufacturing and SWOG S1602 intergroup clinical trial. J Urol 197 (2017), 538–540, 10.1016/j.juro.2016.12.024.
9. Veeratterapillay, R, Heer, R, Johnson, MI, Persad, R, Bach, C, High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage. Curr Urol Rep, 17, 2016, 68, 10.1007/s11934-016-0625-z.
10. Mostafid, AH, Palou Redorta, J, Sylvester, R, Witjes, JA, Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin. Eur Urol 67 (2015), 359–360, 10.1016/j.eururo.2014.11.031.
11. Brausi, M, Morselli, S, The treatment of Ta-T1 bladder cancer in the era of worldwide BCG shortage. Minerva Urol Nefrol 68 (2016), 192–193 http://www.ncbi.nlm.nih.gov/pubmed/26982374.
12. Davies, BJ, Hwang, TJ, Kesselheim, AS, Ensuring access to injectable generic drugs – the case of intravesical BCG for bladder cancer. N Engl J Med 376 (2017), 1401–1403, 10.1056/NEJMp1615697.
13. Messing, EM, The BCG shortage. Bladder Cancer (Amsterdam, Netherlands) 3 (2017), 227–228, 10.3233/BLC-179018.
14. Carrol N Application of Segmented Regression Analysis to the Kaiser Permanente Colorado Critical Drug Interaction Program. http://denversug.org/presentations/2008CODay/ANL-Carroll.pdf. Published 2008. Accessed January 8, 2017.
15. Pugliese, JM, Greene, RN, Peterson, AC, Intravesical therapy use in the high risk patient: practice patterns in an equal access healthcare institution before and after national guidelines. Can J Urol 16 (2009), 4927–4931 http://www.ncbi.nlm.nih.gov/pubmed/20003671.
16. Lambert, EH, Pierorazio, PM, Olsson, CA, Benson, MC, McKiernan, JM, Poon, S, The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100 (2007), 33–36, 10.1111/j.1464-410X.2007.06912.x.
17. Strope, SA, Ye, Z, Hollingsworth, JM, Hollenbeck, BK, Patterns of care for early stage bladder cancer. Cancer 116 (2010), 2604–2611, 10.1002/cncr.25007.
18. Spencer, BA, McBride, RB, Hershman, DL, et al. Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 9 (2013), 92–98, 10.1200/JOP.2011.000480.
19. Zhu, S, Tang, Y, Li, K, et al. Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies. BMC Cancer, 13, 2013, 332, 10.1186/1471-2407-13-332.
20. Rentsch, CA, Birkhäuser, FD, Biot, C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66 (2014), 677–688, 10.1016/j.eururo.2014.02.061.
21. Hofbauer SL, Shariat SF, Chade DC, et al. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for high-risk non-muscle invasive bladder cancer: an alternative during worldwide BCG shortage?Urol Int. 2016;96:46-50. doi:10.1159/000440701.
22. Southwest Oncology Group. S1602: Different Strains of BCG With or Without Vaccine in High Grade Non-Muscle Invasive Bladder Cancer. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03091660.
23. Prasanna, T, Craft, P, Balasingam, G, Haxhimolla, H, Pranavan, G, Intravesical gemcitabine versus intravesical bacillus calmette-guérin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity. Front Oncol, 7, 2017, 260, 10.3389/fonc.2017.00260.
24. Jones, G, Cleves, A, Wilt, TJ, Mason, M, Kynaston, HG, Shelley, M, Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev, 1, 2012, CD009294, 10.1002/14651858.CD009294.pub2.
25. Burke, JM, Lamm, DL, Meng M, V, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 188 (2012), 2391–2397, 10.1016/j.juro.2012.07.097.
26. Dinney, CPN, Fisher, MB, Navai, N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol 190 (2013), 850–856, 10.1016/j.juro.2013.03.030.
27. Kamat, AM, Flaig, TW, Grossman, HB, et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12 (2015), 225–235, 10.1038/nrurol.2015.58.